Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HICKORY phase 3 study of subcutaneous ALXN1850 in adolescents and adults with hypophosphatasia
jRCT2041230107Phase 3Active, not recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jan 2024
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in hypophosphatasia (HPP) comparing Placebo Group with ALXN1850 Group (2 arms). Primary endpoint: Change from baseline in 6-minute walk test at Day 169. Started Jan 2024; status: active, not recruiting.
02
Drugs
efzimfotase alfa
03
Conditions
hypophosphatasia (HPP)
Beyond the preview
Go deeper on jRCT2041230107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041230107.